8-K: Sanara MedTech Inc. Reports Record Revenue for Third Quarter 2024, Despite Increased Net Loss

Sanara MedTech Inc. achieved its twelfth consecutive record net revenue quarter, with a 35% year-over-year increase, but also reported a larger net loss due to increased operating expenses.

Summary

• Sanara MedTech Inc. reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company achieved a record net revenue of $21.7 million, a 35% increase compared to the same quarter in 2023.
• Despite the revenue growth, Sanara reported a net loss of $2.9 million, which is higher than the $1.1 million loss in the third quarter of 2023.
• The increased net loss was primarily due to higher selling, general, and administrative expenses related to the buildout of the Tissue Health Plus (THP) platform, as well as increased interest expense and changes in fair value of earnout liabilities.
• Adjusted EBITDA for the quarter was $0.8 million, compared to $0.3 million in the same period last year.
• The company has expanded its distribution network to over 300 distributors and 2,900 potential sellers.
• Sanara's products are now sold in over 1,200 facilities across 34 states and the District of Columbia.
• The company has agreements to sell its products in more than 4,000 hospitals as of September 30, 2024.
• Sanara invested $5.0 million for a 6.64% ownership in ChemoMouthpiece, LLC and secured an exclusive U.S. distribution agreement.
• The company will host a conference call on November 13, 2024, to discuss the results.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth is strong, the increased net loss and higher operating expenses raise concerns. The strategic investment and new product distribution are positive, but the overall sentiment is neutral to slightly negative due to the financial losses.

Positives

• Sanara MedTech achieved a 35% year-over-year increase in net revenue, reaching $21.7 million.
• The company's Adjusted EBITDA improved to $0.8 million, up from $0.3 million in the same quarter of the previous year.
• Sanara has significantly expanded its distribution network, adding 50 distributors and 500 potential sellers since January 2024.
• The company's products are now sold in more facilities and states, indicating market penetration.
• The investment in ChemoMouthpiece, LLC and the exclusive distribution agreement represent a strategic move into a new market segment.
• The appointment of Keith Myers to the board brings significant experience in healthcare.

Negatives

• Sanara MedTech reported a net loss of $2.9 million for the quarter, which is higher than the $1.1 million loss in the same period last year.
• The increased net loss is primarily due to higher SG&A costs related to the buildout of the THP platform, which increased by approximately $1.2 million.
• The company also experienced higher interest expense of $0.7 million and an increase in expense due to change in fair value of earnout liabilities of $0.8 million.
• Sanara Surgical segment reported a net loss of $0.2 million, compared to a net income of $0.6 million in the same quarter of the previous year.
• The THP segment reported a net loss of $2.7 million, compared to a net loss of $1.7 million in the same quarter of the previous year.

Risks

• The company's increased net loss and higher operating expenses could impact future profitability.
• The buildout of the THP platform is incurring significant costs, which may continue to affect the bottom line.
• Changes in fair value of earnout liabilities can create volatility in reported earnings.
• The company's reliance on debt financing could lead to increased interest expenses.
• The commercial launch of the ChemoMouthpiece product is not expected until 2025, which could delay revenue generation from this investment.

Future Outlook

The company remains focused on executing its growth strategy and delivering value to customers and shareholders. The company expects to commercially launch the ChemoMouthpiece product in 2025.

Management Comments

• Ron Nixon, Sanara's Executive Chairman and CEO, stated that the third quarter of 2024 was Sanara's twelfth consecutive record net revenue quarter.
• Mr. Nixon also mentioned that the company remains focused on continuing to execute its growth strategy and delivering exceptional value to both customers and shareholders.

Industry Context

The company operates in the medical technology sector, specifically focusing on surgical, chronic wound, and skincare markets. The investment in ChemoMouthpiece and the exclusive distribution agreement align with the company's strategy to expand its product offerings and market reach. The company's focus on reducing healthcare expenditures is in line with broader industry trends.

Comparison to Industry Standards

• Sanara's 35% revenue growth is strong compared to many established medical device companies, which often see single-digit growth rates.
• The company's investment in ChemoMouthpiece is similar to other medical device companies that seek to expand their product portfolios through strategic acquisitions and partnerships.
• The increase in SG&A expenses is not uncommon for companies in a growth phase, but the magnitude of the increase is significant and needs to be monitored.
• The company's focus on advanced wound care and surgical tissue repair is a competitive market, with companies like Smith & Nephew, Integra LifeSciences, and Organogenesis being key competitors.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss despite the revenue growth.
• Employees may be impacted by the company's growth and expansion efforts.
• Customers may benefit from the company's expanded product offerings and distribution network.
• Suppliers may see increased demand for their products due to the company's growth.
• Creditors may be impacted by the company's increased debt and interest expenses.

Next Steps

• The company will host a conference call on November 13, 2024, to discuss the results.
• The company plans to commercially launch the ChemoMouthpiece product in 2025.
• The company will continue to focus on executing its growth strategy and expanding its market reach.

Key Dates

Keywords

Sanara MedTech, medical technology, wound care, surgical, net revenue, EBITDA, distribution, ChemoMouthpiece, biologics, tissue repair